The government of india is looking at Covaxin which may be the only affordable vaccine for mass distribution in India. It is the vaccine being developed by a Hyderabad-based company Bharat Biotech along with the indian Council of Medical Research (ICMR) and the National Institute of Virology, Pune.
The vaccine is in its third phase trial and Bharat Biotech on sunday revealed that the vaccine is expected to be 60% efficacious, and certainly more than 50%. Three vaccines which are at the advanced stage across the globe have claimed more than 90% efficiency. 50-60% efficiency is disappointing for sure.
Covaxin may be become available for public use by june 2021 which is quite late. Also, there are reports that a 35-year-old with no comorbidities was hospitalized with viral pneumonitis, a couple of days after being administered the vaccine. He was discharged after a week’s stay in the hospital. On the other side, there are worries about an impending second wave of Corona cases in the country. Already some states are showing the trend which should be worrying. Given the economic condition of the country, one more Lockdown is certainly not possible.
The vaccine is in its third phase trial and Bharat Biotech on sunday revealed that the vaccine is expected to be 60% efficacious, and certainly more than 50%. Three vaccines which are at the advanced stage across the globe have claimed more than 90% efficiency. 50-60% efficiency is disappointing for sure.
Covaxin may be become available for public use by june 2021 which is quite late. Also, there are reports that a 35-year-old with no comorbidities was hospitalized with viral pneumonitis, a couple of days after being administered the vaccine. He was discharged after a week’s stay in the hospital. On the other side, there are worries about an impending second wave of Corona cases in the country. Already some states are showing the trend which should be worrying. Given the economic condition of the country, one more Lockdown is certainly not possible.
